LEOCLAN Co. Ltd. (JP:7681)
:7681
7681 Stock Chart & Stats
¥999.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥999.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥850.00 - ¥1,319.00
Previous CloseN/A
Volume200.00
Average Volume (3M)4.73K
Market Cap
¥5.33B
Enterprise Value¥3.68B
Total Cash (Recent Filing)¥4.78B
Total Debt (Recent Filing)¥7.19M
Price to Earnings (P/E)―
Beta-0.02
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.67%
Share Statistics
EPS (TTM)-13.46
Shares Outstanding5,922,000
10 Day Avg. Volume9,000
30 Day Avg. Volume4,726
Financial Highlights & Ratios
PEG Ratio3.64
Price to Book (P/B)1.18
Price to Sales (P/S)0.31
P/FCF Ratio-57.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthNegligible debt and strong capitalization materially reduce financial risk, giving the company flexibility to fund R&D, product development, or M&A without refinancing pressure. This conservative capital structure supports resilience through demand cycles and preserves strategic optionality.
Revenue ReboundA strong revenue rebound in 2025 after prior declines demonstrates the business can recover demand. If sustained, that top-line momentum helps absorb fixed costs, improve operating leverage, and provide a foundation for more durable margin and cash-flow recovery over the medium term.
Ongoing ProfitabilityDespite thin margins, the company remained profitable in 2025, indicating core business viability. Continued positive earnings provide a base to improve efficiencies and funding for strategic initiatives, making recovery in cash generation and margins more achievable if revenue stabilizes.
Bears Say
Weak Cash GenerationOperating cash flow deterioration and consecutive negative free cash flows constrain the company’s ability to self-fund capex, product investment, or dividends. Persistent cash conversion weakness raises dependence on reserves or external financing and limits strategic flexibility over months.
Volatile Revenue And Thin MarginsMarked top-line volatility combined with compressed net margins reduces earnings predictability and limits the firm's capacity to consistently invest in product development or scale SG&A. This structural instability raises execution risk in a competitive medical-equipment market over the medium term.
Declining Return On EquityA significant fall in ROE signals worsening capital efficiency, suggesting pricing pressure, cost inflation, or unfavorable product mix. Lower returns hinder the company’s ability to generate shareholder value internally and make sustained self-financing of growth more difficult without operational fixes.
7681 FAQ
What was LEOCLAN Co. Ltd.’s price range in the past 12 months?
LEOCLAN Co. Ltd. lowest stock price was ¥850.00 and its highest was ¥1319.00 in the past 12 months.
What is LEOCLAN Co. Ltd.’s market cap?
LEOCLAN Co. Ltd.’s market cap is ¥5.33B.
When is LEOCLAN Co. Ltd.’s upcoming earnings report date?
LEOCLAN Co. Ltd.’s upcoming earnings report date is May 15, 2026 which is in 40 days.
How were LEOCLAN Co. Ltd.’s earnings last quarter?
LEOCLAN Co. Ltd. released its earnings results on Feb 13, 2026. The company reported -¥13.46 earnings per share for the quarter, missing the consensus estimate of N/A by -¥13.46.
Is LEOCLAN Co. Ltd. overvalued?
According to Wall Street analysts LEOCLAN Co. Ltd.’s price is currently Overvalued.
Does LEOCLAN Co. Ltd. pay dividends?
LEOCLAN Co. Ltd. pays a Annually dividend of ¥17 which represents an annual dividend yield of 1.67%. See more information on LEOCLAN Co. Ltd. dividends here
What is LEOCLAN Co. Ltd.’s EPS estimate?
LEOCLAN Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LEOCLAN Co. Ltd. have?
LEOCLAN Co. Ltd. has 5,922,000 shares outstanding.
What happened to LEOCLAN Co. Ltd.’s price movement after its last earnings report?
LEOCLAN Co. Ltd. reported an EPS of -¥13.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of LEOCLAN Co. Ltd.?
Currently, no hedge funds are holding shares in JP:7681
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LEOCLAN Co. Ltd.
LEOCLAN Co.,Ltd. operates as a medical equipment trading company that meets various medical care, welfare, and health needs. It operates through three segments: Medical Total Solutions Business, Remote Image Diagnosis Service Business, and School Lunch Business. The Medical Total Solutions Business segment provides incidental maintenance services; and interior decoration construction and installation works for medical institutions, preventive/health checkup facilities, nursing care/welfare facilities, etc. based on consulting services such as selection of medical equipment, as well as sells medical equipment and medical information systems. The Remote Image Diagnosis Service Business segment offers services in which diagnostic radiology specialists remotely diagnose image data taken by MRI, CT, etc., and provides information. The School Lunch Business segment provides school lunch services, including regular meals, medical meals, and other meals to nursing care and welfare facilities. LEOCLAN Co.,Ltd. was incorporated in 2001 and is headquartered in Settsu, Japan.
Technical Analysis
Cytori Cell Research Institute, Inc.
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―